A breakthrough technique developed by University of Oxford researchers could one day provide tailored repairs for those who suffer brain injuries. The researchers demonstrated for the first time that neural cells can be 3D printed to mimic the architecture of the cerebral cortex. These results have been published in the journal Nature Communications.
The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax\u2019s adjuvant is critical to reducing over half a million malaria-related deaths annually.
The University of Oxford\u2019s commitment to tackling major global health challenges has been strengthened following the endowment of a chair in global health and clinical development. The new permanent post was made possible by a \u00a35 million donation from Brazilian healthcare organisation SAIL for Health.
The UK trial is the next step in the development of a vaccine to protect people against MERS \u2013 a deadly viral illness with no current vaccines and the potential to cause a pandemic.
The MBRRACE-UK Collaboration, jointly led by Nuffield Department of Population Health\u2019s National Perinatal Epidemiology Unit (NPEU) and the University of Leicester\u2019s The Infant Mortality and Morbidity Studies (TIMMS) research group, has published a \u2018State of the Nation\u2019 report on perinatal deaths in babies born in the UK in 2021.
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
The University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax\u2019s adjuvant technology, has been licensed for use in Burkina Faso by the country\u2019s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).
The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully.
A research study led by the University of Oxford provides a transformational new insight into how antimicrobial resistance (AMR) emerges in patients with bacterial infections. The findings, published today in the journal Nature Communications, could help develop more effective interventions to prevent AMR infections developing in vulnerable patients.
Schistosomiasis is a poorly understood tropical disease that is estimated to affect over 250 million people with approximately 779 million people at risk globally. Over 90% of these individuals live in sub-Saharan Africa.
A vaccine developed by the Oxford Vaccine Group\u2019s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from the Jenner Institute (Nuffield Department of Medicine) has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.
The Rockefeller Foundation has announced $3 million in new funding for Global.health (G.h) \u2013 a first-of-its-kind, open-source platform for scientific pandemic data. This will enable it to expand its international partnerships and modernize the global effort around coordinated pandemic prevention, surveillance, and response.
A new study, led by researchers at the University of Oxford, UK, in collaboration with the University of California, Berkeley, USA, published in The Lancet Diabetes & Endocrinology identifies, as early as the 5th month of pregnancy, patterns of fetal abdominal growth associated with maternal lipid metabolites that track newborn growth, adiposity and development into childhood.
Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.
Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization\u2019s (WHO) technical advisory group for integrated clinical care for a period of two years.
Oxford University\u2019s Professor Teresa Lambe, the designer of the vaccine, fears Marburg disease is \u2018now being seen in places where it\u2019s never been seen before\u2019
The new air-powered hand provides a lightweight, low-maintenance and easy-to-use body-powered prosthetic option particularly well suited for children and those in low and middle-income countries.
![\"A](\"https://www.globalhealth.ox.ac.uk/news/oxford-researchers-develop-3d-printing-method-that-shows-promise-for-repairing-brain-injuries/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n